SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market
SureNano Science has initiated an FDA-aligned GLP toxicology and pharmacology program for its lead candidate GEP-44, a multi-receptor peptide for obesity and type 2 diabetes, positioning the company to enter the rapidly growing GLP-1 market projected to reach $200 billion by 2030.
